In fact, CD8+ T cells recognizing nucleocapsid-derived SPRWYFYYL in B*07 (SPR-B07) were found in almost 80% of unexposed subjects (n=9 samples) with a mean frequency of 0.01% (Fig. 2b), presaging the immunodominance of this epitope in convalescent COVID-19 patients, where reactivity was detected in 100% of the samples (n=5) at a mean frequency of 0.29%. Here, CD8A is linked to COVID-19.